Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
11.16 SEK | +5.28% | -15.33% | +231.16% |
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 377M 34.44M 47.08M |
---|---|---|---|---|---|
Net income 2024 * | -37M -3.38M -4.62M | Net income 2025 * | -102M -9.32M -12.75M | EV / Sales 2024 * | - |
Net cash position 2024 * | 18.35M 1.68M 2.29M | Net cash position 2025 * | 57M 5.21M 7.12M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-8.68
x | P/E ratio 2025 * |
-4.51
x | Employees | 13 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 74.72% |
Latest transcript on Ascelia Pharma AB
1 day | +5.28% | ||
1 week | -15.33% | ||
Current month | +21.17% | ||
1 month | +14.58% | ||
3 months | +28.42% | ||
6 months | +273.24% | ||
Current year | +231.16% |
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 49 | 13-12-31 | |
Director of Finance/CFO | 52 | 19-12-31 | |
Chief Tech/Sci/R&D Officer | 40 | 21-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Chairman | 69 | 17-05-31 | |
Niels Mengel
BRD | Director/Board Member | 76 | 99-12-31 |
Director/Board Member | 59 | 16-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-26 | 11.16 | +5.28% | 118,115 |
24-04-25 | 10.6 | +9.84% | 279,835 |
24-04-24 | 9.65 | -23.05% | 458,993 |
24-04-23 | 12.54 | -1.72% | 186,740 |
24-04-22 | 12.76 | -3.19% | 144,180 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 11:29 am
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+231.16% | 34.36M | |
+1.51% | 42.75B | |
+8.57% | 41.34B | |
+49.22% | 41.61B | |
-12.36% | 26.59B | |
+8.92% | 25.49B | |
-25.13% | 18.12B | |
+29.17% | 12.24B | |
-3.12% | 11.76B | |
+6.35% | 11B |
- Stock Market
- Equities
- ACE Stock